ERBB2 and breast carcinoma: In lapatinib-resistant breast cancer cells, HER2 inhibition decreases glycolysis and TCA cycle activity (Supplementary Fig. 5), but decreased flux through these metabolic pathways alone is insufficient to significantly impact cell survival.